Skip to main content
Livermore
Livermore
ZHEN

Xponance, Inc.

SEC CIK
0001637541
Latest filing
Aug 10, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by Xponance, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
25,535
Value
$2.00M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of HALO by Xponance, Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202625,535$2.00M<0.1%−504−1.9%ReducedHolders
Q1 202626,039$1.68M<0.1%+3,074+13.4%AddedHolders
Q4 202522,965$1.55M<0.1%−2,433−9.6%ReducedHolders
Q3 202525,398$1.86M<0.1%−60.0%ReducedHolders
Q2 202525,404$1.32M<0.1%+6,752+36.2%AddedHolders
Q1 202518,652$1.19M<0.1%+198+1.1%AddedHolders
Q4 202418,454$882.3K<0.1%+1,051+6.0%AddedHolders
Q3 202417,403$996.1K<0.1%−359−2.0%ReducedHolders
Q2 202417,762$930.0K<0.1%−1,101−5.8%ReducedHolders
Q1 202418,863$767.3K<0.1%+131+0.7%AddedHolders
Q4 202318,732$692.3K<0.1%−153−0.8%ReducedHolders
Q3 202318,885$721.4K<0.1%−506−2.6%ReducedHolders
Q2 202319,391$699.4K<0.1%−1,568−7.5%ReducedHolders
Q1 202320,959$800.4K<0.1%+91+0.4%AddedHolders
Q4 202220,868$1.19M<0.1%−484−2.3%ReducedHolders
Q3 202221,352$844.0K<0.1%+68+0.3%AddedHolders
Q2 202221,284$936.0K<0.1%+691+3.4%AddedHolders
Q1 202220,593$821.0K<0.1%−14−0.1%ReducedHolders
Q4 202120,607$829.0K<0.1%−632−3.0%ReducedHolders
Q3 202121,239$864.0K<0.1%−238−1.1%ReducedHolders
Q2 202121,477$975.0K<0.1%+7,502+53.7%AddedHolders
Q1 202113,975$583.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.